November 10, 2025

Gastric microbiome shifts track H pylori virulence

Pathogenic bacterial genotypes correlate with distinct microbial communities; overall α-diversity is unchanged, but virulent strains show greater diversity within subgroups as atrophy progresses

Conexiant

November 06, 2025

Microbiome: COVID-19's Hidden Factor?

Pre-pandemic microbiome composition influences severe disease outcomes years later in a population study. 

Conexiant

November 06, 2025

Exercise Patterns and GI Cancer Risk

Consistently meeting—but not exceeding—recommended activity levels offers maximal protection against digestive cancers, new research suggests.

Conexiant

November 05, 2025

FDA Approves First Pediatric IBS-C Treatment

Linzess becomes the first treatment cleared for pediatric irritable bowel syndrome with constipation.

Conexiant

November 05, 2025

Wait Time Equity Elusive in VHA Specialty Care

Over 10 million referrals revealed systemic inequities in access to care.

Conexiant

November 04, 2025

GLP-1s and Tirzepatide: Similar GI Risk

Real-world data show similar rates of severe GI events with semaglutide, dulaglutide, and tirzepatide, reinforcing comparable safety across agents in routine care.

Conexiant

October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant